Q1 2026 was operationally a step forward on multiple fronts: new long-term data from NXTCL-T1D reinforced the durability of the treatment ef...
Redeye’s analyst provides an update following the NextCell's year-end report, which also marks the transition to a standard calendar fiscal ...
Redeye provides commentary on NextCell following the announcement of a SEK15m directed issue and a strategic update relating to its lead can...
NextCell yesterday announced six-year follow-up data for ProTrans in type 1 diabetes, confirming that approximately 50% of endogenous insuli...
Redeye updates on NextCell following its Q4 report, which showed figures largely aligning with estimates.
Redeye provides an update on NextCell following the company’s Q3 report, which came in largely in line with expectations.
Redeye provides commentary on NextCell following recent newsflow including raising SEK36.
Redeye shares its initial impressions of NextCell’s recently announced collaboration with Fujifilm Irvine Scientific, viewing the partnershi...
Redeye updates its view on NextCell following an uneventful Q2 2024/2025 report and the company’s operational update, which offered new pers...
This friday, between 14.00 - 16.00, NextCell Pharma invites investors, analysts, and media to an investor presentation at Redeye after publi...
Redeye returns with an updated take on NextCell following the inconclusive interim analysis, which has led to a sharp decline in the share p...
Redeye comments on the preliminary one-year results from the ProTrans-Young trial, announced by NextCell yesterday after market close ahead ...
Redeye comments on NextCell Pharma ahead of the upcoming interim data from ProTrans-Young, set to be presented in connection with the IDF Wo...
Redeye leaves a short comment on yesterday's announcement that all patients in the ProTrans V study have been treated.
Redeye initiates coverage of NextCell Pharma, a clinical-stage biotech company developing a cell therapy with disease-modifying potential in...
